Food and Drug Administration Commissioner Scott Gottlieb is stepping down in the middle of his fight against “epidemic” teen e-cigarette use, Health and Human Services Sec. Alex Azar announced Tuesday.
Sources close to Gottlieb say he is resigning so that he can spend more time with his wife and three daughters, reported CNBC. They have been living in Westport, Connecticut, while he commutes back and forth to Washington, D.C.
President Donald Trump weighed in on Gottlieb’s pending resignation Tuesday.
“Scott Gottlieb, who has done an absolutely terrific job as Commissioner of the FDA, plans to leave government service sometime next month,” Trump wrote on Twitter after the news broke. “Scott has helped us to lower drug prices, get a record number of generic drugs approved and onto the market, and so many other things. He and his talents will be greatly missed!”
Gottlieb’s successor is unknown. He is slated to hold the position for another month, according to CNBC.
The FDA had just called out pharmacy chain Walgreens and other retailers it said were caught selling tobacco products to minors in a press release Monday. Gottlieb also requested Monday that Walgreens’ management team meet with him.
Gottlieb made enemies out of e-cigarette companies like JUUL by cracking down on them in hopes of cutting down teen vaping, which he called an epidemic.
He didn’t make fans among some in the conservative faction, either, who viewed his policies as anti-free market.
“Commissioner Gottlieb’s tenure at the helm of the FDA started out with great promise in terms of deregulation that put the health of American consumers first,” conservative and libertarian advocacy group FreedomWorks said in a statement Tuesday. “Unfortunately, in the past few months the Commissioner completely reversed course, proposing a nanny state agenda that included a ban on e-cigarette vaping products and limitations on the use of phrases such as ‘almond milk.’”
FreedomWorks is linked to the Koch brothers.
Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact [email protected]